Cereno Scientific AB (publ) (STO: CRNO.B)

Market Cap	1.44B
Revenue (ttm)	86.75M
Net Income (ttm)	-81.12M
Shares Out	281.70M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	717,296
Open	5.18
Previous Close	5.20
Day's Range	4.95 - 5.20
52-Week Range	3.41 - 9.50
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About Cereno Scientific AB

Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CRNO.B

Financial Performance

In 2023, Cereno Scientific AB's revenue was 49.28 million, a decrease of -14.36% compared to the previous year's 57.54 million. Losses were -48.11 million, 74.0% more than in 2022.